| Literature DB >> 28856795 |
P C Ho1.
Abstract
The synthesis of mifepristone, an antiprogestin blocking the action of progesterone at the receptor level, started a new era of medical termination of pregnancy (MTOP). The initial results of MTOP with mifepristone alone were disappointing; however, mifepristone can sensitise the myometrium to the action of prostaglandins. Clinical trials have shown that the sequential administration of mifepristone followed 1-2 days later by a prostaglandin analogue is a safe, effective, and acceptable method for MTOP. This article will review the events and challenges leading to the development of the current evidence-based and yet off-label regimen for first-trimester MTOP. TWEETABLE ABSTRACT: This article reviews the events and challenges in the development of medical termination of pregnancy.Entities:
Keywords: Mifepristone; misoprostol; termination of pregnancy
Mesh:
Substances:
Year: 2017 PMID: 28856795 DOI: 10.1111/1471-0528.14905
Source DB: PubMed Journal: BJOG ISSN: 1470-0328 Impact factor: 6.531